Neoadjuvant chemotherapy for gastric cancer mainly refers to chemotherapy before surgery or radiotherapy for gastric cancer, and is clinically administered to patients with locally advanced gastric cancer, mainly stage III patients. The main purpose of neoadjuvant chemotherapy is to shrink and downgrade the stage of gastric cancer, as well as to facilitate radical surgery, and also to test the sensitivity of chemotherapy as a standardized treatment plan for gastric cancer. The price of neoadjuvant chemotherapy for gastric cancer mainly depends on the used regimen. Currently, the most commonly used clinical regimen is the two-drug combination of oxaliplatin and imported Siroda, which costs about RMB 3,000; if oxaliplatin is applied in combination with domestic capecitabine, the price is about RMB 1,000; if oxaliplatin is applied in combination with imported Estwan, the cost is about RMB 7,000; if oxaliplatin and domestic Tegeo If oxaliplatin and domestic tegeo, the cost is about 3,000 yuan, in addition to other clinical drugs including antiemetic, hepatoprotective and other drugs, the cost needs to be increased by about 200 yuan.